Dermatology

Sidbury covered the similarities and differences between the new guideline updates by the AAD on atopic dermatitis as well as differences with other organizations’ guidelines.

An analysis of survey data from more than 200 patients with atopic dermatitis details treatment satisfaction and provider trust based on racial/ethnic backgrounds of patients.

Jennifer L. Hsiao, MD, discusses what the anticipated JAK inhibitors may provide to patients with HS if FDA-approved in the coming years.

A post-hoc analysis of the ARCADIA program provides insight into the speed of itch relief onset observed with nemolizumab among patients with moderate-to-severe atopic dermatitis.

Matthew Zirwas, MD, provides advice to dermatologists discussing the safety of JAK inhibitor therapies due to their controversial black box warning.

Jonathan Silverberg, MD, PhD, MPH, discusses how the results of the LEVEL UP trial impact treatment decisions for patients with moderate-to-severe atopic dermatitis.

LEVEL UP data presented at RAD 2024 provide additional insight into the phase 3b/4 trial comparing upadacitinib and dupilumab in atopic dermatitis beyond the primary endpoint.

Patients with HS are getting a long-awaited influx of targeted therapies. Jennifer L. Hsiao, MD, discusses their immediate impact.

Study from RAD 2024 finds 36% higher risk of nonmelanoma skin cancer in patients with atopic dermatitis relative to matched controls.

An analysis of data from the LIBERTY AD trial presented at RAD 2024 details the risk of infections observed with dupilumab use with up to 5 years of follow-up.

A real-world analysis of 60 patients suggests traolkinumab was effective in atopic dermatitis, regardless of prior therapy use.

The investigators looked at patients whose severity improved based on either the Physician Global Assessment or the modified Localized Scleroderma Severity Index.

This analysis looked at the efficacy and safety of 200-mg of orally-administered abrocitinib at a rate of once daily, highlighting the drug’s use among patients with CPUO or PN.

The VIO Skin Platform by Enspectra Health was designed to assess lesions indicating either basal cell carcinoma or squamous cell carcinoma.

The month of May 2024 featured several notable studies in the field of dermatology, concerning topics such as a potential eczema flare vaccine, mobile versus in-person health, and skin cancer risk.

These new, phase 3 data from Novartis suggest positive results from treatment with oral remibrutinib for patients with chronic spontaneous urticaria.

The case-control study found the prevalence of MASLD was greater among patients with plaque psoriasis, further suggesting a potential synergistic role between the two.

New phase 2 trial data show more than double the patients receiving daily STS-01 1% cream achieved ≥30% improvement in SALT scores.

A systematic review presented at AAPA 2024 showed insignificant differences in treatment outcomes between oral JAK inhibitors and oral steroids based on alopecia outcomes like SALT.

More than half of patients recruited for this research showed improvements in wound healing, and a significant number had greater wound stability.

This analysis may help bring to light more specific skin cancer-related data on the underserved population of non-Hispanic Black, or NHB, patients.

This analysis highlights the various factors influencing preferences in skin cancer detection between smartphone applications using artificial intelligence versus dermatologists.

The announcement from Bristol Myers Squibb indicates deucravacitinib led to significant improvements in patients’ PASI and sPGA scores after 4 years of treatment.

During this interview segment, Alexis was asked how trifarotene, in combination with an appropriate skincare routine, addresses post-inflammatory hyperpigmentation in skin of color.

This interview featured a discussion of Alexis’s team’s findings on the importance of treating patients with skin of color and acne-induced post-inflammatory hyperpigmentation.